Mary O’Reilly, VP, Inclusion and Organisational Effectiveness, reflects on the International Women’s Day panel and events held at ICON’s global headquarters in Dublin.
On 8 March, ICON hosted a series of live and virtual events across our organisation to recognise International Women’s Day. We encouraged all our office-based employees to attend their local events and wear purple to demonstrate their support. At our global headquarters in Dublin, we had a significant turnout for our coffee morning and panel discussion. It was inspiring to see the demonstrations of support from Dublin and our major hubs in the US and India, as well as our local sites across the globe.
The theme for International Women’s Day this year was #EmbraceEquity to raise awareness of the obstacles that women face in taking advantage of equal opportunities. If opportunities are equal but not equitable, they don’t help to close the gap. From an inclusion and organisational effectiveness perspective, this is an important point of distinction for us to bear in mind for all diversity, equity and inclusion work. During our coffee morning at the Dublin office, I was honoured to moderate a panel with Lucy Gernon of Powerhouse Revolution Coaching, Geraldine Murphy of Evolution Partners and members of ICON’s senior leadership. Together, we discussed women’s empowerment and equity in the workplace. These conversations help to renew our commitment to our shared cause, recalibrate our efforts and surface our learnings and insights to drive action.
Empowerment for individuals
The conversation around gender equity has two key elements, the individual and the organisational. The first part of our panel discussion began with addressing the individual, exploring ways to empower women to recognise their own potential first, espouse a growth mindset and do away with self-limiting beliefs. The panellists discussed imposter syndrome and how it affects more women than men, often causing them to miss out on opportunities they don't feel qualified for. More importantly, the panellists offered concrete steps for deconstructing that internal narrative while empowering oneself to move beyond it.
The most immediate barriers we face can sometimes be our own mindset, especially when we internalise those negative messages. We must first believe in ourselves and our ability to achieve our goals when we put in the work. Sharing these personal stories and strategies among a group of women colleagues and allies inspired a sense of togetherness, reminding women that they have resources to help support them.
Organisational transformation
Women have historically been underrepresented in the workforce, especially at senior leadership levels. The road to equity is a two-way street. Women must be prepared with the tools, skills and confidence to seize opportunities, but organisations must put structures in place to facilitate diversity and deconstruct barriers from higher levels. At ICON, we use simple interviewing quotas to ensure equity in the consideration phase for each open position and key progress indicators to track and measure the impact of our Diversity, Inclusion & Belonging efforts. We have established DI&B community groups (Employee Resource Groups), that actively build a culture of awareness through thought leadership, social connections and education, such as the Community Group Learning Journeys available on our Intranet and Career Hub portals.
At ICON, we are working toward gender parity at senior leadership levels by 2025. About 70% of our employees are women, so parity at senior levels is within reach – we have the talent and the resources and have made steady progress in closing the gender gap at senior leadership roles. Like many other organisations, we must continue transforming the way we lead, including how we characterise good leadership and prioritise those qualities. As we re-evaluate what makes a good leader, emotional intelligence (EQ) and collaboration are increasingly important factors for success. As was stated at the panel discussion, we want to ensure that the best person gets the job, and we know that diversity is what’s best for the organisation as a whole. Ensuring that our senior leadership reflects the diversity of our organisation is the best way forward.
The business case for women
Inclusion, Collaboration and Integrity are part of our core values and they drive our continued efforts to improve DI&B and achieve gender parity. Beyond that, diversity offers many benefits that ripple throughout the levels of our organisation; it fosters innovation and creativity and welcomes unique talent, giving us a competitive advantage and a more agile approach. In prioritising and valuing diversity at the highest levels of our organisation, we create a ripple effect of openness and innovation, collaboration and empowerment. Reaching gender equity is a journey of all levels and every step counts. To reach our goals, everyone must join in.
We will continue our commitment to driving progress and thank everyone who celebrated International Women’s Day with us and participated in this important conversation. Through these events and discussions, we can come together and harness the momentum to affect change. We all benefit when women are empowered, as an organisation and as individuals, so let us continue to #EmbraceEquity together.
Mary O’Reilly explains why ICON is celebrating its first Inclusion Day
Diversity and inclusion in clinical trials
Diversity and inclusion in clinical trials | Whitepaper
Rare Disease Day diversity and inclusion: Raising awareness by running accessible virtual events
Diverse clinical research starts with the healthcare workforce
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel